Soleus Capital Management, L.P. Tg Therapeutics, Inc. Transaction History
Soleus Capital Management, L.P.
- $1.29 Billion
- Q2 2025
A detailed history of Soleus Capital Management, L.P. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 2,243,935 shares of TGTX stock, worth $60.9 Million. This represents 6.26% of its overall portfolio holdings.
Number of Shares
2,243,935
Previous 2,846,703
21.17%
Holding current value
$60.9 Million
Previous $112 Million
28.05%
% of portfolio
6.26%
Previous 9.29%
Shares
11 transactions
Others Institutions Holding TGTX
# of Institutions
404Shares Held
92MCall Options Held
2.24MPut Options Held
1.77M-
Vanguard Group Inc Valley Forge, PA15.8MShares$429 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$309 Million0.0% of portfolio
-
State Street Corp Boston, MA7.62MShares$207 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.49MShares$94.7 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY3.05MShares$82.8 Million0.09% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $3.94B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...